LQDA — Liquidia Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819576 ·
Last close
$68.43
Market Cap
$6.13B
52W High
$93.61
52W Low
$21.15
ADV30
1,257,847
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 171,679,000 | 160,129,000 | 85,517,000 | 74,722,000 | 521,918,000 | 284,181,000 | 326,804,000 |
| Mar 2026 | 132,865,000 | 121,013,000 | 61,504,000 | 52,862,000 | 401,533,000 | 222,786,000 | 292,954,000 |
| Dec 2025 | 92,021,000 | 84,966,000 | 19,787,000 | 14,555,000 | 327,934,000 | 190,680,000 | 283,186,000 |
| Sep 2025 | 54,342,000 | 51,169,000 | 1,767,000 | -3,533,000 | 275,981,000 | 157,496,000 | 253,929,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$47,983,000
Investing CF
$-8,836,000
Financing CF
$17,385,000
CapEx
$-8,836,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.14
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-573,451,000
Inventory
$28,506,000
Receivables
$74,157,000
ST Investments
—
EBIT TTM
$52,221,000
Pretax Income TTM
$26,225,000
Interest Exp TTM
$25,996,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$450,907,008
EBITDA
$169,768,000
Free Cash Flow
$74,296,128
Enterprise Value
$5,872,538,624
Total Cash
$284,180,992
Total Debt
$182,896,000
Shares Out
89,508,891
Trailing EPS
$1.40
Book Value
$2.19
ROE
131.8%
ROA
27.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 158,320,000 | -51,376,000 | -68,924,000 | 327,934,000 | 283,186,000 | 44,748,000 | -35,686,000 |
| Dec 2024 | 13,996,000 | -121,294,000 | -128,291,000 | 230,313,000 | 150,935,000 | 79,378,000 | -93,422,000 |
| Dec 2023 | 17,488,000 | -73,384,000 | -78,502,000 | 118,332,000 | 71,039,000 | 47,293,000 | -41,564,000 |
| Dec 2022 | 15,935,000 | -38,770,000 | -41,015,000 | 129,198,000 | 38,776,000 | 90,422,000 | -28,588,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$5.65
Max Pain — expiry 2026-10-02
max pain strike: $68.00 · spot: $73.68 · call oi: 14,867 · put oi: 15,599
Expected Move to 2026-10-02:
±$12.43
(16.87%) —
implied range
$61.25 –
$86.11
· ATM straddle on $74.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | $6.01B | $301.52 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.82B | $89.70 | — |
| COGT | Cogent Biosciences, Inc. | $5.61B | $32.31 | — |
| TVTX | Travere Therapeutics, Inc. | $5.60B | $59.44 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.59B | $84.46 | — |
News headlines (Yahoo Finance, 1h cache)
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
2026-09-23 15:14 · Yahoo
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
2026-09-11 18:21 · Yahoo
Does FDA Fast Track For YUTREPIA In SSc Raynaud’s Change The Bull Case For Liquidia (LQDA)?
2026-09-05 03:08 · Yahoo
Liquidia (LQDA) Stock Looks Stretched On Earnings But Reasonable On Broader Checks
2026-09-04 15:09 · Yahoo
Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations
2026-09-03 14:10 · Yahoo
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
2026-09-02 12:30 · Yahoo
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
2026-09-01 12:30 · Yahoo
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
2026-08-31 14:14 · Yahoo
Is the Options Market Predicting a Spike in Liquidia Stock?
2026-08-31 13:29 · Yahoo
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
2026-08-19 18:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.